New personalised cancer care initiative launched

25 October 2010

CRUK’s parallel programme seeks to harness the benefits of genomic medicine to improve cancer diagnosis and management. It will work with selected NHS hospitals and laboratories, and companies Pfizer and Life Technologies, to improve genetic testing services and collect genetic data from patients with certain tumour types linked to information on outcomes to inform research.

The aim is to expand the use of genetic analysis of tumours to inform patient care, including prognosis and treatment choices, and to drive the development of new drugs targeted to different tumour types and sub-types. 

More from us